Lipid–Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma
Dehui Fu, Chao Li, Yongwang Huang Department of Ear-Nose-Throat (ENT), The Second Hospital of Tianjin Medical University, Tianjin, 300211, People’s Republic of ChinaCorrespondence: Yongwang HuangDepartment of Ear-Nose-Throat, The Second Hospital of Tianjin Medical University, No. 23 Pingji...
Main Authors: | Fu D, Li C, Huang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-04-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/lipidndashpolymer-hybrid-nanoparticle-based-combination-treatment-with-peer-reviewed-article-OTT |
Similar Items
-
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
by: Xue C, et al.
Published: (2016-03-01) -
Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
by: Eleonore Longton, et al.
Published: (2018-10-01) -
Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows in vitro and in vivo antitumor efficacy toward the treatment of nasopharyngeal cancer cells
by: Dongmei Liu, et al.
Published: (2021-01-01) -
Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01) -
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
by: Yuan Zhang, et al.
Published: (2019-06-01)